It was concluded that tocilizumab (added with institutional treatment module) showed better therapeutic efficacy than institutional treatment protocol (alone) in terms of resolving inflammation (by lowering inflammatory parameters except for CRP), coagulopathy (reducing coagulation parameters except platelet count) and cytokine release syndrome (CRS), thereby improving disease prognosis in COVID-19 patients. Here, CRP is linked to congenital rubella syndrome.